COPD cohort demographic data
| Sample size | 13 | 10 |
| Age (years) (SD) | 63.5 (10.07) | Between 18 and 48* |
| Male (%) | 5 (38) | 2 (20) |
| Current smoker (%) | 3 (23) | NA |
| FEV1 % predicted | 30.6 (12.6) | NA |
| Mean FEV1/FVC ratio (SD) | 31.4 (7.7) | NA |
| Exacerbations per year (SD) | 5.2 (4.5) | NA |
| Antimicrobials | None within 6 months | |
| Prophylactic macrolides | 2 | NA |
| Self-management | 10 | NA |
| Amoxicillin† | 5 | NA |
| Doxycycline | 5 (1 in combination) | NA |
| Levofloxacin | 1 | NA |
*Individual ages of healthy volunteers not collected.
†Includes one on co-amoxiclav.
COPD, chronic obstructive pulmonary disease; FEV1, forced Eexpiratory Vvolume in 1 s; FVC, forced vital capacity; NA, not applicable.